Eliem Therapeutics Stock Performance
ELYM Stock | USD 4.56 0.19 4.00% |
Eliem Therapeutics holds a performance score of 8 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of -1.05, which means a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Eliem Therapeutics are expected to decrease slowly. On the other hand, during market turmoil, Eliem Therapeutics is expected to outperform it slightly. Use Eliem Therapeutics potential upside, and the relationship between the total risk alpha and kurtosis , to analyze future returns on Eliem Therapeutics.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Eliem Therapeutics are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Eliem Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (4.00) | Five Day Return 5.31 | Year To Date Return 62.86 | Ten Year Return (71.32) | All Time Return (71.32) |
1 | Will Eliem Therapeutics Inc Lag the Rest of the Stocks in the Healthcare Sector - InvestorsObserver | 03/05/2024 |
2 | Acquisition by Emily Pimblett of 40000 shares of Eliem Therapeutics subject to Rule 16b-3 | 03/18/2024 |
3 | ELYM Stock Alert Halper Sadeh LLC Is Investigating Whether the Merger of Eliem Therapeutics, Inc. Is Fair to Shareholders | 04/11/2024 |
4 | Disposition of tradable shares by Ratcliffe Liam of Eliem Therapeutics subject to Rule 16b-3 | 04/15/2024 |
Begin Period Cash Flow | 43.6 M |
Eliem |
Eliem Therapeutics Relative Risk vs. Return Landscape
If you would invest 297.00 in Eliem Therapeutics on January 18, 2024 and sell it today you would earn a total of 159.00 from holding Eliem Therapeutics or generate 53.54% return on investment over 90 days. Eliem Therapeutics is currently generating 1.015% in daily expected returns and assumes 9.6346% risk (volatility on return distribution) over the 90 days horizon. In different words, 85% of stocks are less volatile than Eliem, and 80% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
Risk |
Eliem Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eliem Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Eliem Therapeutics, and traders can use it to determine the average amount a Eliem Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1054
Best Portfolio | Best Equity | |||
Good Returns | ||||
Average Returns | ||||
Small Returns | ELYM | |||
Cash | Small Risk | Average Risk | High Risk | Huge Risk |
Negative Returns |
Estimated Market Risk
9.63 actual daily | 85 85% of assets are less volatile |
Expected Return
1.01 actual daily | 19 81% of assets have higher returns |
Risk-Adjusted Return
0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Eliem Therapeutics is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eliem Therapeutics by adding it to a well-diversified portfolio.
Eliem Therapeutics Fundamentals Growth
Eliem Stock prices reflect investors' perceptions of the future prospects and financial health of Eliem Therapeutics, and Eliem Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Eliem Stock performance.
Return On Equity | -0.3 | ||||
Return On Asset | -0.11 | ||||
Current Valuation | 25.22 M | ||||
Shares Outstanding | 27.72 M | ||||
Price To Book | 1.13 X | ||||
EBITDA | (40.27 M) | ||||
Net Income | (35.12 M) | ||||
Cash And Equivalents | 122.95 M | ||||
Cash Per Share | 4.63 X | ||||
Total Debt | 349 K | ||||
Debt To Equity | 0 % | ||||
Current Ratio | 17.48 X | ||||
Book Value Per Share | 3.88 X | ||||
Cash Flow From Operations | (20.6 M) | ||||
Earnings Per Share | (1.30) X | ||||
Market Capitalization | 126.4 M | ||||
Total Asset | 110.47 M | ||||
Retained Earnings | (155.98 M) | ||||
Working Capital | 107.42 M | ||||
About Eliem Therapeutics Performance
To evaluate Eliem Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Eliem Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Eliem Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Eliem Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Eliem's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Last Reported | Projected for Next Year | ||
Days Of Inventory On Hand | 0.00 | 0.00 | |
Return On Tangible Assets | (0.32) | (0.33) | |
Return On Capital Employed | (0.37) | (0.39) | |
Return On Assets | (0.32) | (0.33) | |
Return On Equity | (0.33) | (0.34) |
Things to note about Eliem Therapeutics performance evaluation
Checking the ongoing alerts about Eliem Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Eliem Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.Eliem Therapeutics is way too risky over 90 days horizon | |
Eliem Therapeutics appears to be risky and price may revert if volatility continues | |
Net Loss for the year was (35.12 M) with profit before overhead, payroll, taxes, and interest of 0. | |
Eliem Therapeutics currently holds about 122.95 M in cash with (20.6 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.63, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
Eliem Therapeutics has a frail financial position based on the latest SEC disclosures | |
Roughly 67.0% of the company shares are held by institutions such as insurance companies | |
Latest headline from MacroaxisInsider: Disposition of tradable shares by Ratcliffe Liam of Eliem Therapeutics subject to Rule 16b-3 |
- Analyzing Eliem Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eliem Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Eliem Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eliem Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eliem Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eliem Therapeutics' stock. These opinions can provide insight into Eliem Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eliem Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Eliem Stock, please use our How to Invest in Eliem Therapeutics guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for Eliem Stock analysis
When running Eliem Therapeutics' price analysis, check to measure Eliem Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eliem Therapeutics is operating at the current time. Most of Eliem Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eliem Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eliem Therapeutics' price. Additionally, you may evaluate how the addition of Eliem Therapeutics to your portfolios can decrease your overall portfolio volatility.
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
Stocks Directory Find actively traded stocks across global markets | |
Money Managers Screen money managers from public funds and ETFs managed around the world |
Is Eliem Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eliem Therapeutics. If investors know Eliem will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eliem Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.30) | Return On Assets (0.11) | Return On Equity (0.30) |
The market value of Eliem Therapeutics is measured differently than its book value, which is the value of Eliem that is recorded on the company's balance sheet. Investors also form their own opinion of Eliem Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Eliem Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eliem Therapeutics' market value can be influenced by many factors that don't directly affect Eliem Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eliem Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eliem Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eliem Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.